Found 98 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase 2 Randomized Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …
A Randomized Double-blind Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …
A 6-month prospective randomized double-blind placebo-controlled clinical trial investigating the efficacy safety and tolerability of two different doses of buntanetap or placebo in patients with early Parkinsons disease
A double-blind study to investigate efficacy and safety of buntanetap compared with placebo in participants with early PD
A Phase II randomized double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
A Randomized Double-Blind Placebo-Controlled Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B …
A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1)
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in adult participants with primary ITP.
A Phase 3 Double-Blind Randomized Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
A PHASE 2 MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF REC-4881 IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
This is a multicenter, randomized, double-blind, placebo-controlled two-part trial in patients with FAP who have previously undergone a colectomy/proctocolectomy using the invesitgational product REC-4881.
A Randomized Double-Blind Parallel Placebo-Controlled Study of the Efficacy Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis
This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group, proof-of-concept study. The primary purpose of this study is to evaluate the effect of dupilumab on relieving EoE clinical symptoms and reducing esophageal inflammation in adults. Currently there is no regulatory-approved endpoint for drug registration for this indication. Published clinical trials …
MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis
This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with …
Please choose between Voice or SMS based delivery of verification code
or